Journal article
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
Abstract
BACKGROUND: Lung cancer is the most common cause of cancer-related death among males and the second leading cause among females globally. Checkpoint inhibitors re-engage the immune system to fight cancer. This review evaluates phase III data on the use of checkpoint inhibitors in the treatment of advanced NSCLC and addresses PD-L1 expression in predicting efficacy.
METHODS: Six phase III clinical trials investigating checkpoint inhibitors for …
Authors
Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao M-S; McLeod D; Hirsh V
Journal
Cancer Treatment Reviews, Vol. 65, , pp. 65–77
Publisher
Elsevier
Publication Date
April 2018
DOI
10.1016/j.ctrv.2018.02.005
ISSN
0305-7372